Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - TG THERAPEUTICS, INC. | Q3_10Q2016.htm |
| EX-32.2 - EXHIBIT 32-2 - TG THERAPEUTICS, INC. | exhibit32-2.htm |
| EX-31.2 - EXHIBIT 31-2 - TG THERAPEUTICS, INC. | exhibit31-2.htm |
| EX-31.1 - EXHIBIT 31-1 - TG THERAPEUTICS, INC. | exhibit31-1.htm |
Exhibit 32.1
STATEMENT
OF CHIEF EXECUTIVE OFFICER OF
TG
THERAPEUTICS, INC.
PURSUANT
TO 18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the quarterly report of TG Therapeutics, Inc. (the
“Company”) on Form 10-Q for the period ended September
30, 2016 as filed with the Securities and Exchange Commission (the
“Report”), I, Michael S. Weiss, Chief Executive Officer
of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
that, based on my knowledge:
1) The
Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
2) The
information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
Date: November 9,
2016
|
|
/s/ Michael S.
Weiss
|
|
|
Michael S.
Weiss
Executive Chairman,
Interim Chief Executive Officer and President
Principal Executive
Officer
|
|